Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. (Q44358596)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

hepatocellular carcinoma

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Yu-Tseng Chu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Wen-Yi Shau

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

15 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

506-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Influence of chronic coinfection with hepatitis B and C virus on liver histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Dual chronic hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

The secret of immortal time bias in epidemiologic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-304370

10.1136/GUTJNL-2012-304370

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23676440%20AND%20SRC:MED&resulttype=core&format=json